Literature DB >> 7259337

Basal and pentagastrin-stimulated levels of calcitonin in thyroid and peripheral veins during normocalcemia and chronic hypercalcemia in humans.

M Ericsson, M Berg, S Ingemansson, B Jernby, J Järhult.   

Abstract

The calcitonin secretion from the thyroid C-cells was studied with a peroperative method. The calcitonin concentrations in thyroid venous effluent and peripheral veins were determined in patients who underwent operations because of thyroid and parathyroid disease. In normocalcemia the thyroid vein level of calcitonin was significantly higher than that in peripheral vein. In chronic hypercalcemia no gradient over the thyroid was demonstrable. After injection of pentagastrin into a thyroid artery a very pronounced, but transient, increase in calcitonin concentration was registered. No difference in peak value between normo- and hypercalcemia was demonstrable. The peripheral vein level was unchanged. The peroperative method is very sensitive. A marked peak in thyroid vein corresponds to unchanged values in peripheral vein. The method invites further studies with other secretagogues and receptor-blocking substances.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7259337      PMCID: PMC1345228          DOI: 10.1097/00000658-198108000-00002

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  15 in total

Review 1.  Endocrine secretory mechanisms. A review.

Authors:  P E Lacy
Journal:  Am J Pathol       Date:  1975-04       Impact factor: 4.307

2.  Plasma calcitonin in normal man. Differences between men and women.

Authors:  H Heath; G W Sizemore
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

3.  Serum calcitonin in medullary thyroid carcinoma. Radioimmunoassay technique and diagnostic value.

Authors:  S Almqvist; M Telenius-Berg; B Wästhed
Journal:  Acta Med Scand       Date:  1974-09

4.  Immunoassay of human calcitonin.

Authors:  A H Tashijan; B G Howland; K E Melvin; C S Hill
Journal:  N Engl J Med       Date:  1970-10-22       Impact factor: 91.245

5.  Calcitonin levels in thyroid-vein blood of man.

Authors:  O L Silva; K L Becker; J L Doppman; R H Snider; C F Moore
Journal:  Am J Med Sci       Date:  1975 Jan-Feb       Impact factor: 2.378

6.  Screening for medullary carcinoma of the thyroid in families with Sipple's syndrome: evaluation of new stimulation tests.

Authors:  M Telenius-Berg; S Almqvist; B Berg; P Hedner; S Ingemansson; S Tibblin; B Wasthed
Journal:  Eur J Clin Invest       Date:  1977-02       Impact factor: 4.686

7.  Radioimmunoassay of calcitonin in human plasma.

Authors:  O L Silva; R H Snider; K L Becker
Journal:  Clin Chem       Date:  1974-03       Impact factor: 8.327

8.  Plasma human calcitonin (hCT) levels in normal and pathologic conditions, and their responses to short calcium or tetragastrin infusion.

Authors:  I Adachi; K Abe; M Tanaka; K Yamaguchi; S Miyakawa
Journal:  Endocrinol Jpn       Date:  1976-12

9.  Secretion of thyroxine, 3,5,3'-triiodothyronine and 3,3'5'-triiodothyronine in euthyroid man.

Authors:  U Westgren; A Melander; S Ingemansson; A Burger; S Tibblin; E Wåhlin
Journal:  Acta Endocrinol (Copenh)       Date:  1977-02

10.  The early diagnosis of medullary carcinoma of the thyroid gland in patients with multiple endocrine neoplasia type II.

Authors:  S A Wells; D A Ontjes; C W Cooper; J F Hennessy; G J Ellis; H T McPherson; D C Sabiston
Journal:  Ann Surg       Date:  1975-10       Impact factor: 12.969

View more
  2 in total

1.  Different effects of hypercalcemic state induced by Walker tumor (HWCS 256) and 1,25 (OH)D3 intoxication on rat thyroid C cells. An ultrastructural, immunocytochemical, and biochemical study.

Authors:  E Rix; F Raue; I Deutschle; R Ziegler
Journal:  Histochemistry       Date:  1984

2.  Thyroid venous catheterization in the early diagnosis of familial medullary thyroid carcinoma.

Authors:  S A Wells; S B Baylin; I S Johnsrude; D P Harrington; G Mendelsohn; D J Ontjes; C W Cooper
Journal:  Ann Surg       Date:  1982-11       Impact factor: 12.969

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.